BRAFTOVI® and MEKTOVI® were evaluated in the COLUMBUS Phase III randomized trial, where they achieved 14.9 months mPFS and 33.6 months mOS, showing the potential to become an important therapeutic option in patients with advanced BRAF-mutant melanoma.1,2

In the 5-year COLUMBUS update, BRAFTOVI®+MEKTOVI® combination demonstrated continued long-term benefits and a consistent safety profile with previous observations in patients with BRAF-mutant melanoma.3

EXPLORE COLUMBUS RESULTS

Image
Braftovi_Mektovi_R_RGB

 

Image
Hourglass icon

We have been on the market for

0

DAYS

Image
World map icon

We are present in

0

COUNTRIES

Image
Location icon

We are present in

0

CONTINENTS

Image
Laughing children

Taking care, living better

The objective of our cancer research is to improve the treatment of patients suffering from pathologies for which there are significant unmet therapeutic needs, always staying true to the Pierre Fabre's values, and with the objective of contributing to the well-being of individuals.

FIND OUT MORE ABOUT US

EU Healthcare Professionals​

This is an international website for BRAFTOVI® + MEKTOVI® dedicated to EU Healthcare professionals ​​(outside the UK and ROI).

IMPORTANT: the information on this website is based on the European Summaries of Product Characteristics of BRAFTOVI® and MEKTOVI®. Prescribing Information and indication may vary per country. You must refer to your country prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

I certify that: 

I am a Healthcare Professional in the EU (outside the UK and ROI) and I have read the information above.

Patients / Non EU Healthcare Professionals

This is an international website for BRAFTOVI® + MEKTOVI® dedicated to EU Healthcare Professionals (outside the UK and ROI). 

I am a patient or a Healthcare Professional outside the EU.

https://www.pierre-fabre.com/en